TheraCryf to unveil full year results, host Ox-1 program webinar

ALDERLEY PARK - TheraCryf plc (AIM:TCF), a clinical stage drug development company specializing in neuropsychiatry and oncology, has announced it will release its full-year results for the fiscal year ending March 31, 2025, on Tuesday, June 3, 2025. The company will also host a live presentation on the same day at 1 pm BST, which will be accessible via the Investor Meet Company platform.

The presentation will be led by CEO Dr. Huw Jones, CFO Toni Hänninen, and Chair Dr. Alastair Smith. Following the announcement of the results, TheraCryf will conduct a separate webinar on June 11, 2025, at 11:30 am BST, to provide an in-depth analysis of its Ox-1 addiction program. Dr. Helen Kuhlman, TheraCryf’s CBO, and neuroscientist Dr. Fraser Murray will spearhead the session.

Both events are open to all shareholders and potential investors. Participants can submit questions up to 24 hours before each event through the Investor Meet Company dashboard or during the live presentations. Those already following TheraCryf on the Investor Meet Company platform will be automatically invited, while new attendees can register for the event.

TheraCryf, headquartered at Alderley Park, Cheshire, is focused on developing drug treatments for brain disorders, with a pipeline that includes therapies for addiction, anxiety, fatigue, narcolepsy, glioblastoma, and neurodevelopmental disorders. The company’s strategy involves partnering with mid-size to large pharmaceutical companies for larger trials and commercialization after achieving compelling data sets to preclinical and/or clinical proof of concept.

The company maintains collaborations with prominent universities and hospitals, including the University of Manchester, Università di Roma La Sapienza, Erasmus Medical (TASE:BLWV) Centre in Rotterdam, Kings College London, and the University of Michigan. TheraCryf is listed on the AIM market of the London Stock Exchange (LON:LSEG) under the ticker symbol TCF.

The information regarding the company’s upcoming financial results and the Ox-1 program webinar is based on a press release statement from TheraCryf plc.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.